Introduction

The world-wide Anticoagulants market is expected to garner USD 39 billion by 2026 and the market is expected to register CAGR growth over 7.9% during the next eight years.

Market Dynamics

Growing need for controlling the diseases such as kidney diseases and cardiovascular diseases is expected to propel the market growth over forecast period. In addition to this, rise in obesity patient and hence related disorders is another factor which is ultimately boosting the adoption of Anticoagulants in the healthcare areas and hence driving the market growth.

Market Insights

The worldwide anticoagulants market is anticipated to show significant growth during the forecast period, due to the increasing prevalence of cardiovascular disorders, venous thromboembolism (VTE), and others. Also, increasing adoption of novel oral anticoagulants (NOACs), and rising awareness of NOACs and it’s benefits in the emerging regions are boosting the market growth. The increasing obesity issues and rising population of elderly people, and rise in demand of novel therapeutics are some of the other factors driving the market growth. On the other hand, higher price of NOACs and lack of awareness about the anticoagulants to hamper the market growth.

The anticoagulant are drugs which functions as a blood thinners. The anticoagulants are used for preventing or reducing the coagulation of blood also used to prolong the blood clotting time. These drugs are majorly used for high risk of blood clots in various medical conditions. The importance of anticoagulants in preventing the clot formation in the human body is foreseen to be prime factor driving the market growth. Also, anticoagulants are used in the prevention of enlargement of the existing clots in the vein or arteries so that the health hazards are reduced to significant level.

Such properties of Anticoagulants are making them one of the irreplaceable part in the operational areas associated with the heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. In addition, anticoagulants plays an outstanding role while performing the surgery.

Market Segmentation

Market By Route of Administration

• Oral
• Injectable

Market By Drug Class

• Factor XA Inhibitors (NOAC/DOAC)
• Heparins
• Direct Thrombin Inhibitors
• Vitamin K Antagonists

Market By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market By Indication

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Atrial Fibrillation
• Heart Attack

Market By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Rest of MEA

Regional Insights

In terms of consumption of anticoagulants, the North America was the dominant region in the year 2018 and the similar trend is expected to continue over forecast period due to rapid increase in the surgeries such as hip and knee surgeries in this region. Europe region is following the North America in terms of demand for anticoagulants. Increase in geriatric population is expected to be one of the key factor boosting the demand for anticoagulant in this region.

On the other hand, APAC region is expected to register significant CAGR growth rate over forecast period. The increasing health issues due to changing lifestyle as well as increasing surgical operations in this region are some of the prime factors accelerating the demand for anticoagulants in this region. Also, increasing network of healthcare facilities is expected to be another factor creating a demand for anticoagulants.

Market Participants

The key players operating in the global anticoagulants market are Bristol-Myers Squibb Company, Pfizer, Inc., Bayer Healthcare, Sanofi, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., and Daiichi Sankyo Company Limited.

TABLE OF CONTENT